Follica sees bushy prospects in baldness therapy

The San Francisco Chronicle takes a hard look at the new baldness therapies in the pipeline, concentrating much of its attention on Follica, which is focusing on microdermabrasion to remove an outer layer of dead cells. That process, encouraged by a new therapy, would allow deeper cells to spur the growth of new hair follicles. "We view it as a very early, very high-risk project," InterWest Partners' Chris Ehrlich tells the newspaper. "But if it works, it would be great."

Insurers have proved reluctant to provide coverage for baldness therapies, but developers are counting on consumers who are passionate about avoiding balding.

- read the article from the San Francisco Chronicle

Suggested Articles

CureVac named a permanent CEO, Franz-Werner Haas, and signed Novartis alum, Igor Splawski, Ph.D. as its new top scientist.

J&J studied the drug in midphase obesity clinical trials, but Merck sees it as a potential treatment for nonalcoholic steatohepatitis.

The Big Pharma paid $134 million to enter into the two partnerships but then dropped the projects after Voyager completed research activities.